- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Selected as a TA.
- Process:
- STA Standard
- ID number:
- 6756
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Amgen Limited (teprotumumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- British Thyroid Foundation
- The Thyroid Trust
- Professional groups
- Royal College of Ophthalmologists
- Royal College of Physicians
- Society for Endocrinology
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 March 2026 | In progress. Deferred appraisal of D1. The appraisal will continue from the second committee meeting. The date of the second committee meeting is to be confirmed. |
| 10 April 2024 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual